Celgene's chemotherapy Abraxane stumbles in pivotal pancreatic cancer study
Days after Celgene’s Abraxane secured approval in combination with Roche’s checkpoint inhibitor for frontline use in triple negative breast cancer, the US drugmaker reported that the chemotherapy failed to improve progression-free survival in a pivotal study involving pancreatic cancer patients who had undergone surgical resection.
Abraxane is already approved for use in various cancers: metastatic breast cancer, metastatic non-small cell lung cancer (NSCLC) as well as metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.